# Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital

> **NIH NIH P30** · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $1,270,598

## Abstract

CENTER OVERVIEW: PROJECT SUMMARY
The goal of the Center for the Study of Inflammatory Bowel Disease (CSIBD) is to promote and facilitate
digestive disease research that yields insight into IBD pathogenesis and leads to therapeutic advancements.
This objective remains unchanged since the inception of the CSIBD in 1991, guiding the Center through nearly
three decades of discovery in genetic underpinnings of IBD risk and protection, mechanisms of epithelial and
immune function, and contributions to etiology from the gut microbiome. The CSIBD is home to 89 members
that received over $44 million in digestive disease research funding. CSIBD research is driven by a central
hypothesis that the major forms of IBD result from interactions between genetically-determined and permissive
features of the individual, gut microbiome, and other environmental factors that dysregulate intestinal immune
and inflammatory pathways. Investigations are broadly divided into six areas: human genetics and physiological
mechanisms; the gut microbiome in health and disease; cell circuits and systems biology; innate and adaptive
immunity; chemical biology and therapeutic science; and clinical translational science and patient impact.
Collaborations within the CSIBD generated a single-cell atlas of the human colon during ulcerative colitis (UC)
that revealed new inflammatory populations associated with disease and anti-TNF therapy resistance, pinpointed
cell types in which UC susceptibility genes function, and established a framework for elucidating mechanisms of
inflammation and treatment response. Incorporating longitudinal microbiome metagenomic, metatranscriptomic,
and metabolomic profiles with host molecular measurements, the Integrative Human Microbiome Project
catalogued host–microbe relationships in IBD and laid a foundation for the next phase in clinical translation of
the gut microbiome. The overall specific aims of the CSIBD are to (1) promote research in basic science areas
relevant to better understanding of epithelial biology and mucosal immune function in IBD; (2) advance our
understanding of gut pathophysiology by examining the gut as a circuit, studying the core components of gut
intra- and inter-cellular interactions that determine health and disease; (3) promote the study of the pathogenesis
of IBD; (4) promote interactions among scientists exploring diverse fields that share relevance to IBD; (5) promote
translational IBD research; (6) attract investigators to the study of IBD and mucosal immunology; and (7) provide
an environment and mechanism to foster development of young investigators focused on IBD. A central priority
of the CSIBD is to serve as a nexus of fundamental science, clinical translation, and patient benefit by enabling
collaborations across biomedical disciplines and catalyzing advancements that address critical barriers to
building a more detailed understanding of IBD and its causes. Four biomedical cores offer state-of-the-art
resources and...

## Key facts

- **NIH application ID:** 10048890
- **Project number:** 2P30DK043351-31
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Ramnik J Xavier
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $1,270,598
- **Award type:** 2
- **Project period:** 1997-01-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10048890

## Citation

> US National Institutes of Health, RePORTER application 10048890, Center for the Study of Inflammatory Bowel Disease at Massachusetts General Hospital (2P30DK043351-31). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10048890. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*